Virend K. Somers
Research Subjects
Research Interests
Virend K. Somers has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Krzysztof Narkiewicz
Department of Hypertension and Diabetology, Medical University of Gdańsk, 80-210 Gdańsk, Poland
11 shared publications - Nicola Montano
University of Milan
8 shared publications Philippe J. H. van de Borne
From the Cardiovascular Division, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa
5 shared publicationsPhilippe van de Borne
Hypertension Clinic, Department of Cardiology, Erasme Hospital, Belgium
5 shared publicationsCatherine A. Pesek
From the Cardiovascular Division, Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa
4 shared publications- Mark Eric Dyken
The University of Iowa Roy J. and Lucille A. Carver College of Medicine
4 shared publications
Latest Publications
- 1 June 2011
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29, e141
MUSCLE SYMPATHETIC NERVE ACTIVITY IS NOT INFLUENCED BY LONG-TERM SLOW BREATHING TRAINING IN HYPERTENSION
- 1 June 2011
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 29, e141
MUSCLE SYMPATHETIC NERVE ACTIVITY IS NOT INFLUENCED BY LONG-TERM SLOW BREATHING TRAINING IN HYPERTENSION
- 1 February 2004
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 22 (Suppl. 1) , S22
DOBUTAMINE POTENTIATES CHEMOREFLEX SENSITIVITY TO HYPOXIA IN NORMAL HUMANS IN A DOSE DEPENDENT MANNER
- 1 February 2004
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 22 (Suppl. 1) , S22
DOBUTAMINE POTENTIATES CHEMOREFLEX SENSITIVITY TO HYPOXIA IN NORMAL HUMANS IN A DOSE DEPENDENT MANNER
- 22 August 2002
- Vol. 5 (5) , 216-221
Dopamine and congestive heart failure: pharmacology, clinical use, and precautions.
It has been suggested that low dose dopamine (<5 micro g/kg/min) may have renal protective effects. There are, however, no randomized, double blind, placebo controlled studies to support these observations. The contribution of improvements in cardiac output (due to beta(1)-adrenergic stimulation) to increases in renal blood flow, independent of changes in renal vasodilation, are unclear. There is little evidence to support any dopamine induced clinically significant improvement in renal function in the presence of diuretics. Given the limited evidence of benefits of low dose dopamine, potential adverse effects need to be recognized, particularly in patients with heart failure. Low dose dopamine induces hypoxemia in patients with heart failure by impairing both gas exchange and ventilatory responses and thus could precipitate respiratory decompensation in patients being weaned from ventilators. Sleep disordered breathing is highly prevalent in heart failure patients-the effects of dopamine induced chemoreflex inhibition may prove deleterious in this condition. We therefore believe that current knowledge of the risk/benefit ratio of the use of "renal doses" of dopamine does not support its widespread use in patients with heart failure, particularly in those patients in whom respiratory function is compromised. (c)1999 by CHF, Inc.
- 22 August 2002
- Vol. 5 (5) , 216-221
Dopamine and congestive heart failure: pharmacology, clinical use, and precautions.
It has been suggested that low dose dopamine (<5 micro g/kg/min) may have renal protective effects. There are, however, no randomized, double blind, placebo controlled studies to support these observations. The contribution of improvements in cardiac output (due to beta(1)-adrenergic stimulation) to increases in renal blood flow, independent of changes in renal vasodilation, are unclear. There is little evidence to support any dopamine induced clinically significant improvement in renal function in the presence of diuretics. Given the limited evidence of benefits of low dose dopamine, potential adverse effects need to be recognized, particularly in patients with heart failure. Low dose dopamine induces hypoxemia in patients with heart failure by impairing both gas exchange and ventilatory responses and thus could precipitate respiratory decompensation in patients being weaned from ventilators. Sleep disordered breathing is highly prevalent in heart failure patients-the effects of dopamine induced chemoreflex inhibition may prove deleterious in this condition. We therefore believe that current knowledge of the risk/benefit ratio of the use of "renal doses" of dopamine does not support its widespread use in patients with heart failure, particularly in those patients in whom respiratory function is compromised. (c)1999 by CHF, Inc.
- 1 August 1999
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 17 (8) , 1061-1064
Debating sympathetic overactivity as a hallmark of human obesity
- 1 August 1999
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 17 (8) , 1061-1064
Debating sympathetic overactivity as a hallmark of human obesity
- 20 July 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (3) , 262-267
Enhanced Sympathetic and Ventilatory Responses to Central Chemoreflex Activation in Heart Failure
Background —Sympathetic activation and respiratory abnormalities may each be implicated in the pathophysiology of congestive heart failure (CHF). Chemoreflexes are an important mechanism regulating both sympathetic drive and breathing. We therefore tested the hypothesis that chemoreflex function is altered in CHF. Methods and Results —We compared ventilatory, sympathetic, heart rate, and blood pressure responses to hypoxia, hypercapnia, and the cold pressor test in 9 patients with CHF and 9 control subjects matched for age and body mass index. Baseline muscle sympathetic nerve activity (MSNA) was higher in the patients with CHF compared with control subjects (47±8 versus 23±3 bursts per minute, P P =0.03) and heart rate (7.0±2.1 versus 0.6±1.2 bpm, P =0.02). Despite higher ventilation, which inhibits sympathetic activity, the MSNA increase in patients with CHF was also greater than that in control subjects (58±12% versus 21±9%, P =0.03). Ventilatory, autonomic, and blood pressure responses to hypoxia and the cold pressor test in CHF patients were not different from those in control subjects. Conclusions —Chronic heart failure is characterized by a selective potentiation of ventilatory and sympathetic responses to central chemoreceptor activation by hypercapnia.
- 20 July 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 100 (3) , 262-267
Enhanced Sympathetic and Ventilatory Responses to Central Chemoreflex Activation in Heart Failure
Background —Sympathetic activation and respiratory abnormalities may each be implicated in the pathophysiology of congestive heart failure (CHF). Chemoreflexes are an important mechanism regulating both sympathetic drive and breathing. We therefore tested the hypothesis that chemoreflex function is altered in CHF. Methods and Results —We compared ventilatory, sympathetic, heart rate, and blood pressure responses to hypoxia, hypercapnia, and the cold pressor test in 9 patients with CHF and 9 control subjects matched for age and body mass index. Baseline muscle sympathetic nerve activity (MSNA) was higher in the patients with CHF compared with control subjects (47±8 versus 23±3 bursts per minute, P P =0.03) and heart rate (7.0±2.1 versus 0.6±1.2 bpm, P =0.02). Despite higher ventilation, which inhibits sympathetic activity, the MSNA increase in patients with CHF was also greater than that in control subjects (58±12% versus 21±9%, P =0.03). Ventilatory, autonomic, and blood pressure responses to hypoxia and the cold pressor test in CHF patients were not different from those in control subjects. Conclusions —Chronic heart failure is characterized by a selective potentiation of ventilatory and sympathetic responses to central chemoreceptor activation by hypercapnia.
- 1 May 1999
- Published by Wolters Kluwer Health in Hypertension
- Vol. 33 (5) , 1153-1158
Human Obesity Is Characterized by a Selective Potentiation of Central Chemoreflex Sensitivity
—The chemoreflexes are an important mechanism for regulation of both breathing and autonomic cardiovascular function. Obesity is associated with an increased risk of alveolar hypoventilation and carbon dioxide retention, suggesting that abnormalities in chemoreflex control mechanisms may be implicated. We tested the hypothesis that chemoreflex function is altered in obesity. We compared ventilatory, sympathetic, heart rate, and blood pressure responses to hypercapnia, hypoxia, and the cold pressor test in 14 obese subjects and 14 normal-weight subjects matched for age and gender. During hypercapnia, the increase in minute ventilation was significantly greater in obese subjects (7.0±0.3 L/min) than in normal-weight subjects (3.3±1.1 L/min; P =0.03). Despite higher minute ventilation during hypercapnia in obese subjects, the increase in muscle sympathetic nerve activity was similar in obese and normal-weight subjects. When the inhibitory influence of breathing during hypercapnia was eliminated by apnea, the increase in sympathetic nerve activity in obese subjects (99±16%) was greater than in normal-weight subjects (44±16%; P =0.02). The magnitude of the ventilatory and autonomic responses to hypoxia and the cold pressor test was similar in obese and normal-weight subjects. We conclude that chemoreflex responses to hypercapnia are potentiated in eucapnic obese subjects. In contrast, responses to hypoxia and to the excitatory cold pressor stimulus in obese subjects are similar to those in normal-weight subjects. Thus, obesity is characterized by selective potentiation of central chemoreflex sensitivity.
- 1 May 1999
- Published by Wolters Kluwer Health in Hypertension
- Vol. 33 (5) , 1153-1158
Human Obesity Is Characterized by a Selective Potentiation of Central Chemoreflex Sensitivity
—The chemoreflexes are an important mechanism for regulation of both breathing and autonomic cardiovascular function. Obesity is associated with an increased risk of alveolar hypoventilation and carbon dioxide retention, suggesting that abnormalities in chemoreflex control mechanisms may be implicated. We tested the hypothesis that chemoreflex function is altered in obesity. We compared ventilatory, sympathetic, heart rate, and blood pressure responses to hypercapnia, hypoxia, and the cold pressor test in 14 obese subjects and 14 normal-weight subjects matched for age and gender. During hypercapnia, the increase in minute ventilation was significantly greater in obese subjects (7.0±0.3 L/min) than in normal-weight subjects (3.3±1.1 L/min; P =0.03). Despite higher minute ventilation during hypercapnia in obese subjects, the increase in muscle sympathetic nerve activity was similar in obese and normal-weight subjects. When the inhibitory influence of breathing during hypercapnia was eliminated by apnea, the increase in sympathetic nerve activity in obese subjects (99±16%) was greater than in normal-weight subjects (44±16%; P =0.02). The magnitude of the ventilatory and autonomic responses to hypoxia and the cold pressor test was similar in obese and normal-weight subjects. We conclude that chemoreflex responses to hypercapnia are potentiated in eucapnic obese subjects. In contrast, responses to hypoxia and to the excitatory cold pressor stimulus in obese subjects are similar to those in normal-weight subjects. Thus, obesity is characterized by selective potentiation of central chemoreflex sensitivity.
- 30 March 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 99 (12) , 1606-1610
Sympathetic Rhythmicity in Cardiac Transplant Recipients
Background —Variability of R-R interval and muscle sympathetic nerve activity (MSNA) occurs predominantly at a low frequency (LF, ±0.1 Hz) and a high frequency (HF, ±0.25 Hz) in normal humans. Increased sympathetic drive in normal humans is associated with an increased LF component of the R-R interval and MSNA. Patients with severe heart failure have high sympathetic activity but decreased or absent LF power of both R-R and MSNA. We tested the hypothesis that this dysfunction in autonomic modulation in heart failure can be reversed by heart transplantation. Methods and Results —We performed spectral analysis of resting MSNA, R-R interval, and respiration in 9 patients with heart transplants, 9 chronic heart failure patients, and 9 normal control subjects, all closely matched for age, sex, and body mass index. MSNA (bursts per minute) was higher in patients with heart transplants (74±3) than either patients with heart failure (56±6) or normal subjects (40±4) ( P P P Conclusions —Cardiac transplantation does not reduce MSNA. However, LF oscillations in sympathetic activity are restored after transplantation such that the MSNA oscillatory profile is similar to that observed in normal subjects.
- 30 March 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 99 (12) , 1606-1610
Sympathetic Rhythmicity in Cardiac Transplant Recipients
Background —Variability of R-R interval and muscle sympathetic nerve activity (MSNA) occurs predominantly at a low frequency (LF, ±0.1 Hz) and a high frequency (HF, ±0.25 Hz) in normal humans. Increased sympathetic drive in normal humans is associated with an increased LF component of the R-R interval and MSNA. Patients with severe heart failure have high sympathetic activity but decreased or absent LF power of both R-R and MSNA. We tested the hypothesis that this dysfunction in autonomic modulation in heart failure can be reversed by heart transplantation. Methods and Results —We performed spectral analysis of resting MSNA, R-R interval, and respiration in 9 patients with heart transplants, 9 chronic heart failure patients, and 9 normal control subjects, all closely matched for age, sex, and body mass index. MSNA (bursts per minute) was higher in patients with heart transplants (74±3) than either patients with heart failure (56±6) or normal subjects (40±4) ( P P P Conclusions —Cardiac transplantation does not reduce MSNA. However, LF oscillations in sympathetic activity are restored after transplantation such that the MSNA oscillatory profile is similar to that observed in normal subjects.
- 9 March 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 99 (9) , 1183-1189
Selective Potentiation of Peripheral Chemoreflex Sensitivity in Obstructive Sleep Apnea
Background —The chemoreflexes are an important mechanism for regulation of both breathing and autonomic cardiovascular function. Abnormalities in chemoreflex mechanisms may be implicated in increased cardiovascular stress in patients with obstructive sleep apnea (OSA). We tested the hypothesis that chemoreflex function is altered in patients with OSA. Methods and Results —We compared ventilatory, sympathetic, heart rate, and blood pressure responses to hypoxia, hypercapnia, and the cold pressor test in 16 untreated normotensive patients with OSA and 12 normal control subjects matched for age and body mass index. Baseline muscle sympathetic nerve activity (MSNA) was higher in the patients with OSA than in the control subjects (43±4 versus 21±3 bursts per minute; P P =0.02), heart rate (10±1 versus 7±1 bpm; P =0.03), and mean arterial pressure (7±2 versus 0±2 mm Hg; P =0.001) than control subjects. Despite higher ventilation and blood pressure (both of which inhibit sympathetic activity) in OSA patients, the MSNA increase during hypoxia was similar in OSA patients and control subjects. When the sympathetic-inhibitory influence of breathing was eliminated by apnea during hypoxia, the increase in MSNA in OSA patients (106±20%) was greater than in control subjects (52±23%; P =0.04). Prolongation of R-R interval with apnea during hypoxia was also greater in OSA patients (24±6%) than in control subjects (7±5%) ( P =0.04). Autonomic, ventilatory, and blood pressure responses to hypercapnia and the cold pressor test in OSA patients were not different from those observed in control subjects. Conclusions —OSA is associated with a selective potentiation of autonomic, hemodynamic, and ventilatory responses to peripheral chemoreceptor activation by hypoxia.
- 9 March 1999
- Published by Wolters Kluwer Health in Circulation
- Vol. 99 (9) , 1183-1189
Selective Potentiation of Peripheral Chemoreflex Sensitivity in Obstructive Sleep Apnea
Background —The chemoreflexes are an important mechanism for regulation of both breathing and autonomic cardiovascular function. Abnormalities in chemoreflex mechanisms may be implicated in increased cardiovascular stress in patients with obstructive sleep apnea (OSA). We tested the hypothesis that chemoreflex function is altered in patients with OSA. Methods and Results —We compared ventilatory, sympathetic, heart rate, and blood pressure responses to hypoxia, hypercapnia, and the cold pressor test in 16 untreated normotensive patients with OSA and 12 normal control subjects matched for age and body mass index. Baseline muscle sympathetic nerve activity (MSNA) was higher in the patients with OSA than in the control subjects (43±4 versus 21±3 bursts per minute; P P =0.02), heart rate (10±1 versus 7±1 bpm; P =0.03), and mean arterial pressure (7±2 versus 0±2 mm Hg; P =0.001) than control subjects. Despite higher ventilation and blood pressure (both of which inhibit sympathetic activity) in OSA patients, the MSNA increase during hypoxia was similar in OSA patients and control subjects. When the sympathetic-inhibitory influence of breathing was eliminated by apnea during hypoxia, the increase in MSNA in OSA patients (106±20%) was greater than in control subjects (52±23%; P =0.04). Prolongation of R-R interval with apnea during hypoxia was also greater in OSA patients (24±6%) than in control subjects (7±5%) ( P =0.04). Autonomic, ventilatory, and blood pressure responses to hypercapnia and the cold pressor test in OSA patients were not different from those observed in control subjects. Conclusions —OSA is associated with a selective potentiation of autonomic, hemodynamic, and ventilatory responses to peripheral chemoreceptor activation by hypoxia.
- 1 December 1998
- Published by Wolters Kluwer Health in Hypertension
- Vol. 32 (6) , 1039-1043
Baroreflex Control of Sympathetic Nerve Activity and Heart Rate in Obstructive Sleep Apnea
—Patients with obstructive sleep apnea are at increased risk for hypertension. The mechanisms underlying this increased risk are not known. We tested the hypothesis that obstructive sleep apnea, independent of factors such as hypertension, obesity, and age, is characterized by impairment of baroreflex sensitivity. We measured muscle sympathetic nerve activity (MSNA) and heart rate responses to activation and deactivation of baroreceptors in newly diagnosed, never treated, normotensive patients with obstructive sleep apnea. These responses were compared with those obtained in healthy control subjects closely matched for age, body mass index, and blood pressure. Heart rate and MSNA changes during infusion of phenylephrine (baroreceptor activation) were similar in the control subjects and patients with sleep apnea. Infusion of nitroprusside (baroreceptor deactivation) elicited similar decreases in mean arterial pressure (MAP) but lesser MSNA increases in patients with sleep apnea than in control subjects. Calculation of ΔMSNA/ΔMAP ratio revealed that baroreflex regulation of sympathetic activity for similar blood pressure changes was diminished in patients with sleep apnea in comparison to normal control subjects ( P =0.01). However, increases in heart rate during nitroprusside infusion were comparable in both groups. Sympathetic, blood pressure and heart rate responses to the cold pressor test were also similar in the 2 groups. Our results indicate that normotensive patients with sleep apnea have a selective impairment of the sympathetic response to baroreceptor deactivation but not to baroreceptor activation or to the cold pressor test. The impairment of baroreflex sympathetic modulation in patients with sleep apnea is not accompanied by any impairment of baroreflex control of heart rate.
- 1 December 1998
- Published by Wolters Kluwer Health in Hypertension
- Vol. 32 (6) , 1039-1043
Baroreflex Control of Sympathetic Nerve Activity and Heart Rate in Obstructive Sleep Apnea
—Patients with obstructive sleep apnea are at increased risk for hypertension. The mechanisms underlying this increased risk are not known. We tested the hypothesis that obstructive sleep apnea, independent of factors such as hypertension, obesity, and age, is characterized by impairment of baroreflex sensitivity. We measured muscle sympathetic nerve activity (MSNA) and heart rate responses to activation and deactivation of baroreceptors in newly diagnosed, never treated, normotensive patients with obstructive sleep apnea. These responses were compared with those obtained in healthy control subjects closely matched for age, body mass index, and blood pressure. Heart rate and MSNA changes during infusion of phenylephrine (baroreceptor activation) were similar in the control subjects and patients with sleep apnea. Infusion of nitroprusside (baroreceptor deactivation) elicited similar decreases in mean arterial pressure (MAP) but lesser MSNA increases in patients with sleep apnea than in control subjects. Calculation of ΔMSNA/ΔMAP ratio revealed that baroreflex regulation of sympathetic activity for similar blood pressure changes was diminished in patients with sleep apnea in comparison to normal control subjects ( P =0.01). However, increases in heart rate during nitroprusside infusion were comparable in both groups. Sympathetic, blood pressure and heart rate responses to the cold pressor test were also similar in the 2 groups. Our results indicate that normotensive patients with sleep apnea have a selective impairment of the sympathetic response to baroreceptor deactivation but not to baroreceptor activation or to the cold pressor test. The impairment of baroreflex sympathetic modulation in patients with sleep apnea is not accompanied by any impairment of baroreflex control of heart rate.
- 17 November 1998
- Published by Wolters Kluwer Health in Circulation
- Vol. 98 (20) , 2105-2107
Chronic Orthostatic Intolerance
- 17 November 1998
- Published by Wolters Kluwer Health in Circulation
- Vol. 98 (20) , 2105-2107
Chronic Orthostatic Intolerance